Overview

An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This was an extension study for the study FE200486 CS12 (NCT00819156). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained. The study was terminated when all ongoing participants had been treated for at least 5 years (including one year in the main study).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ferring Pharmaceuticals